Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03985943




Registration number
NCT03985943
Ethics application status
Date submitted
11/06/2019
Date registered
14/06/2019
Date last updated
14/08/2024

Titles & IDs
Public title
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Secondary ID [1] 0 0
RD.06.SPR.118161
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Moderate-to-Severe Atopic Dermatitis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Nemolizumab

Placebo comparator: Placebo - Placebo

Experimental: Nemolizumab - Nemolizumab Active


Treatment: Drugs: Placebo
Placebo

Treatment: Drugs: Nemolizumab
Nemolizumab
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population
Timepoint [1] 0 0
Week 16
Primary outcome [2] 0 0
Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population
Timepoint [2] 0 0
Week 16
Primary outcome [3] 0 0
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population
Timepoint [3] 0 0
Week 16
Primary outcome [4] 0 0
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population
Timepoint [4] 0 0
Week 16
Secondary outcome [1] 0 0
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population
Timepoint [1] 0 0
Week 16
Secondary outcome [2] 0 0
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population
Timepoint [2] 0 0
Week 16
Secondary outcome [3] 0 0
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population
Timepoint [3] 0 0
Week 16
Secondary outcome [4] 0 0
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population
Timepoint [4] 0 0
Week 16
Secondary outcome [5] 0 0
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population
Timepoint [5] 0 0
Week 16
Secondary outcome [6] 0 0
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population
Timepoint [6] 0 0
Week 16
Secondary outcome [7] 0 0
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT Population
Timepoint [7] 0 0
Week 4
Secondary outcome [8] 0 0
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus Population
Timepoint [8] 0 0
Week 4
Secondary outcome [9] 0 0
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT Population
Timepoint [9] 0 0
Week 4
Secondary outcome [10] 0 0
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus Population
Timepoint [10] 0 0
Week 4
Secondary outcome [11] 0 0
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT Population
Timepoint [11] 0 0
Week 2
Secondary outcome [12] 0 0
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus Population
Timepoint [12] 0 0
Week 2
Secondary outcome [13] 0 0
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT Population
Timepoint [13] 0 0
Week 1
Secondary outcome [14] 0 0
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus Population
Timepoint [14] 0 0
Week 1

Eligibility
Key inclusion criteria
Key

* Male or female subjects aged greater than and equal to (>=) 12 years at the screening visit.
* Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for at least 2 years before the screening visit.
* Eczema Area and Severity Index (EASI) score >=16 at the screening and baseline visits.
* Investigator Global Assessment (IGA) score >= 3 (scale of 0 to 4) at the screening and baseline visits.
* AD involvement >= 10 percent (%) of body surface area (BSA) at screening and baseline visits.
* Peak Pruritus Numerical Rating Scale (PPNRS) score of at least 4.0 at the screening and baseline visit.
* Documented recent history of inadequate response to topical medications (topical corticosteroids [TCS] with or without Topical calcineurin inhibitors [TCI]).
* Female subjects of childbearing potential (that is, fertile, following menarche and until becoming postmenopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection.

Key
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Body weight (<) 30 kilograms (kg).
* Exacerbation of asthma requiring hospitalization in the preceding 12 months. Uncontrolled asthma in the preceding 3 months.
* Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit.
* Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical study.

Note: Subjects with chronic, stable use of prophylactic treatment for recurrent herpes viral infection can be included in this clinical study.

* History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, example, monoclonal antibody) or to any of the study drug excipients.
* Any clinically significant issue, based on investigator judgement.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/06/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
11/08/2022
Sample size
Target
Accrual to date
Final
941
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Galderma Investigational Site 5441 - Darlinghurst
Recruitment hospital [2] 0 0
Galderma Investigational Site 5759 - Kogarah
Recruitment hospital [3] 0 0
Galderma Investigational Site 6152 - Westmead
Recruitment hospital [4] 0 0
Galderma Investigational Site 5638 - Benowa
Recruitment hospital [5] 0 0
Galderma Investigational Site 6161 - Brisbane
Recruitment hospital [6] 0 0
Galderma Investigational Site 6159 - Woodville
Recruitment hospital [7] 0 0
Galderma Investigational Site 6131 - Carlton
Recruitment hospital [8] 0 0
Galderma Investigational Site 5366 - East Melbourne
Recruitment hospital [9] 0 0
Galderma Investigational Site 5458 - Parkville
Recruitment hospital [10] 0 0
Galderma Investigational Site 5453 - Fremantle
Recruitment hospital [11] 0 0
Galderma Investigational Site 6153 - Victoria Park
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4217 - Benowa
Recruitment postcode(s) [5] 0 0
4102 - Brisbane
Recruitment postcode(s) [6] 0 0
5011 - Woodville
Recruitment postcode(s) [7] 0 0
3053 - Carlton
Recruitment postcode(s) [8] 0 0
3002 - East Melbourne
Recruitment postcode(s) [9] 0 0
3050 - Parkville
Recruitment postcode(s) [10] 0 0
6160 - Fremantle
Recruitment postcode(s) [11] 0 0
6100 - Victoria Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Maine
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Montana
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
Nevada
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
South Dakota
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
Austria
State/province [24] 0 0
Styria
Country [25] 0 0
Austria
State/province [25] 0 0
Wien
Country [26] 0 0
Austria
State/province [26] 0 0
Vienna
Country [27] 0 0
Canada
State/province [27] 0 0
Alberta
Country [28] 0 0
Canada
State/province [28] 0 0
British Columbia
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Canada
State/province [30] 0 0
Niagara Falls
Country [31] 0 0
Canada
State/province [31] 0 0
Ottawa
Country [32] 0 0
Canada
State/province [32] 0 0
Saint John
Country [33] 0 0
Canada
State/province [33] 0 0
Waterloo
Country [34] 0 0
Czechia
State/province [34] 0 0
Brno
Country [35] 0 0
Czechia
State/province [35] 0 0
Náchod
Country [36] 0 0
Czechia
State/province [36] 0 0
Olomouc
Country [37] 0 0
Czechia
State/province [37] 0 0
Prague
Country [38] 0 0
Czechia
State/province [38] 0 0
Praha
Country [39] 0 0
Germany
State/province [39] 0 0
Hesse
Country [40] 0 0
Germany
State/province [40] 0 0
Niedersachesen
Country [41] 0 0
Germany
State/province [41] 0 0
NRW
Country [42] 0 0
Germany
State/province [42] 0 0
Schleswig-Holst
Country [43] 0 0
Germany
State/province [43] 0 0
Bad Bentheim
Country [44] 0 0
Germany
State/province [44] 0 0
Berlin
Country [45] 0 0
Germany
State/province [45] 0 0
Bielefeld
Country [46] 0 0
Germany
State/province [46] 0 0
Buxtehude
Country [47] 0 0
Germany
State/province [47] 0 0
Darmstadt
Country [48] 0 0
Germany
State/province [48] 0 0
Dülmen
Country [49] 0 0
Germany
State/province [49] 0 0
Münster
Country [50] 0 0
Germany
State/province [50] 0 0
Osnabrück
Country [51] 0 0
Germany
State/province [51] 0 0
Stuttgart
Country [52] 0 0
Korea, Republic of
State/province [52] 0 0
Bucheon
Country [53] 0 0
Korea, Republic of
State/province [53] 0 0
Busan
Country [54] 0 0
Korea, Republic of
State/province [54] 0 0
Gyeonggi-do
Country [55] 0 0
Korea, Republic of
State/province [55] 0 0
Incheon
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Seoul
Country [57] 0 0
Latvia
State/province [57] 0 0
Liepaja
Country [58] 0 0
Latvia
State/province [58] 0 0
Riga
Country [59] 0 0
Latvia
State/province [59] 0 0
Talsi
Country [60] 0 0
Lithuania
State/province [60] 0 0
Kaunas
Country [61] 0 0
Lithuania
State/province [61] 0 0
Klaipeda
Country [62] 0 0
Lithuania
State/province [62] 0 0
Vilnius
Country [63] 0 0
Netherlands
State/province [63] 0 0
Groningen
Country [64] 0 0
Netherlands
State/province [64] 0 0
Rotterdam
Country [65] 0 0
Netherlands
State/province [65] 0 0
Utrecht
Country [66] 0 0
New Zealand
State/province [66] 0 0
Hamilton
Country [67] 0 0
New Zealand
State/province [67] 0 0
Wellington
Country [68] 0 0
Poland
State/province [68] 0 0
Czestochowa
Country [69] 0 0
Poland
State/province [69] 0 0
Gdansk
Country [70] 0 0
Poland
State/province [70] 0 0
Gdynia
Country [71] 0 0
Poland
State/province [71] 0 0
Katowice
Country [72] 0 0
Poland
State/province [72] 0 0
Lublin
Country [73] 0 0
Poland
State/province [73] 0 0
Ostrowiec Swietokrzyski
Country [74] 0 0
Poland
State/province [74] 0 0
Poznan
Country [75] 0 0
Poland
State/province [75] 0 0
Szczecin
Country [76] 0 0
Poland
State/province [76] 0 0
Warszawa
Country [77] 0 0
Poland
State/province [77] 0 0
Wroclaw
Country [78] 0 0
Poland
State/province [78] 0 0
Lódz
Country [79] 0 0
Spain
State/province [79] 0 0
Alicante
Country [80] 0 0
Spain
State/province [80] 0 0
Barcelona
Country [81] 0 0
Spain
State/province [81] 0 0
Las Palmas De Gran Canaria
Country [82] 0 0
Spain
State/province [82] 0 0
Madrid
Country [83] 0 0
Spain
State/province [83] 0 0
Pamplona
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Barnsley
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Blackpool
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Cannock
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Glasgow
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Liverpool
Country [89] 0 0
United Kingdom
State/province [89] 0 0
London
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Manchester
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Stockton-on-Tees

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Galderma R&D
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.
Trial website
https://clinicaltrials.gov/study/NCT03985943
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03985943